Indication

Multiple endocrine neoplasia

Multiple endocrine neoplasia refers to a group of rare, inherited autosomal dominant syndromes characterized by the development of benign or malignant tumors in two or more endocrine glands. Read more about Multiple endocrine neoplasia

217 drugs 140 manufacturers

Advertisement

Drugs that treat it

Common Multiple endocrine neoplasia therapies.

Showing 19–27 of 217 drugs

FAMOTIDINE

MULTIPLE ENDOCRINE NEOPLASIA·+13
PADDOCK LABS.

FAMOTIDINE

PEPTIC ULCER AGENTS·MULTIPLE ENDOCRINE NEOPLASIA·+13
LUPIN PHARMACEU

FAMOTIDINE

MULTIPLE ENDOCRINE NEOPLASIA·+13
WEST-WARD,INC.

FAMOTIDINE

MULTIPLE ENDOCRINE NEOPLASIA·+13
APP PHARMACEUTI
Filter & compare in the drug finder →Opens the drug finder with Multiple endocrine neoplasia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Multiple endocrine neoplasia.

Multiple endocrine neoplasia refers to a group of rare, inherited autosomal dominant syndromes characterized by the development of benign or malignant tumors in two or more endocrine glands.

Primarily affecting hormone-producing tissues, these disorders commonly involve the parathyroid glands, pituitary gland, endocrine pancreas, thyroid gland, and adrenal glands.

Pathophysiologically driven by germline variants—most notably in tumor suppressor genes such as *MEN1* or proto-oncogenes such as *RET*—these conditions lead to cellular hyperplasia, neoplastic transformation, and autonomous hormone hypersecretion.

Clinically, affected individuals present with manifestations of hormonal excess and tumor mass effect, frequently including hyperparathyroidism, medullary thyroid carcinoma, and pheochromocytoma depending on the specific syndrome classification.

Personalize your experience

Follow Multiple endocrine neoplasia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it